StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd (TEVA) stock

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30128% above fair value
$42.62+0.05 (+0.12%)

Close on Nov 17, 2026Market cap $49.66BP/E 71.0Yield –

Teva Pharmaceutical Industries free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Teva Pharmaceutical Industries's free cash flow for the twelve months ending Jun 30, 2026 was $1.35B, up 51.5% year over year. For fiscal 2025 it was $1.15B, up 53.3% from the year before. Over ten years it grew -13.3% a year on average. The highest annual figure on record is $4.77B in fiscal 2015.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.15B+53.3%
FY2024Dec 31, 2024$749.00M-11.0%
FY2023Dec 31, 2023$842.00M-19.2%
FY2022Dec 31, 2022$1.04B+341.5%
FY2021Dec 31, 2021$236.00M-63.0%
FY2020Dec 31, 2020$638.00M+186.1%
FY2019Dec 31, 2019$223.00M-87.6%
FY2018Dec 31, 2018$1.80B+32.9%
FY2017Dec 31, 2017$1.35B-54.8%
FY2016Dec 31, 2016$2.99B-37.3%
FY2015Dec 31, 2015$4.77B+13.6%
FY2014Dec 31, 2014$4.20B+90.3%
FY2013Dec 31, 2013$2.21B-36.4%
FY2012Dec 31, 2012$3.47B+12.6%
FY2011Dec 31, 2011$3.08B-10.1%
FY2010Dec 31, 2010$3.43B+29.1%
FY2009Dec 31, 2009$2.65B+4.1%
FY2008Dec 31, 2008$2.55B+100.6%
FY2007Dec 31, 2007$1.27B–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$307.00M+134.4%
Q1 FY2026Mar 31, 2026-$208.00M–
Q4 FY2025Dec 31, 2025$1.02B+127.8%
Q3 FY2025Sep 30, 2025$233.00M-57.2%
Q2 FY2025Jun 30, 2025$131.00M+2083.3%
Q1 FY2025Mar 31, 2025-$232.00M–
Q4 FY2024Dec 31, 2024$446.00M-58.1%
Q3 FY2024Sep 30, 2024$545.00M–
Q2 FY2024Jun 30, 2024$6.00M-97.1%
Q1 FY2024Mar 31, 2024-$248.00M–
Q4 FY2023Dec 31, 2023$1.07B+28.2%
Q3 FY2023Sep 30, 2023-$144.00M-134.2%
Q2 FY2023Jun 30, 2023$205.00M–
Q1 FY2023Mar 31, 2023-$284.00M–
Q4 FY2022Dec 31, 2022$831.00M+174.3%
Q3 FY2022Sep 30, 2022$421.00M+9.9%
Q2 FY2022Jun 30, 2022-$4.00M-103.8%
Q1 FY2022Mar 31, 2022-$206.00M–
Q4 FY2021Dec 31, 2021$303.00M+95.5%
Q3 FY2021Sep 30, 2021$383.00M+133.5%
Q2 FY2021Jun 30, 2021$105.00M-26.1%
Q1 FY2021Mar 31, 2021-$555.00M-413.6%
Q4 FY2020Dec 31, 2020$155.00M-63.0%
Q3 FY2020Sep 30, 2020$164.00M+5.1%
Q2 FY2020Jun 30, 2020$142.00M–
Q1 FY2020Mar 31, 2020$177.00M–
Q4 FY2019Dec 31, 2019$419.00M+172.1%
Q3 FY2019Sep 30, 2019$156.00M-44.7%
Q2 FY2019Jun 30, 2019-$339.00M-1403.8%
Q1 FY2019Mar 31, 2019-$13.00M-101.0%
Q4 FY2018Dec 31, 2018$154.00M-74.0%
Q3 FY2018Sep 30, 2018$282.00M-51.6%
Q2 FY2018Jun 30, 2018$26.00M-89.3%
Q1 FY2018Mar 31, 2018$1.33B–
Q4 FY2017Dec 31, 2017$592.00M–
Q3 FY2017Sep 30, 2017$583.00M-53.0%
Q2 FY2017Jun 30, 2017$242.00M–
Q1 FY2017Mar 31, 2017-$66.00M–
Q4 FY2016Dec 31, 2016-$243.00M–
Q3 FY2016Sep 30, 2016$1.24B–

More Teva Pharmaceutical Industries figures

See a number that looks wrong?